191 related articles for article (PubMed ID: 25431479)
1. Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia.
Kaur V; Mehta P; Johnsurd J; Govindarajan R
Blood; 2014 Nov; 124(23):3503-5. PubMed ID: 25431479
[No Abstract] [Full Text] [Related]
2. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
3. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
Wierda WG; Byrd JC; O'Brien S; Coutre S; Barr PM; Furman RR; Kipps TJ; Burger JA; Stevens DA; Sharman J; Ghia P; Flinn IW; Zhou C; Ninomoto J; James DF; Tam CS
Br J Haematol; 2019 Jul; 186(1):184-188. PubMed ID: 30740654
[No Abstract] [Full Text] [Related]
4. Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.
Giovanni B; Ibatici A; Sola S; Brunasso AMG; Massone C
Am J Dermatopathol; 2020 Feb; 42(2):148-150. PubMed ID: 30839345
[No Abstract] [Full Text] [Related]
5. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.
Wang SY; Ebert T; Jaekel N; Schubert S; Niederwieser D; Al-Ali HK
Ann Hematol; 2015 Aug; 94(8):1419-20. PubMed ID: 25903044
[No Abstract] [Full Text] [Related]
6. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
Mato AR; Islam P; Daniel C; Strelec L; Kaye AH; Brooks S; Ganetsky A; Nasta S; Porter DL; Svoboda J; Nabhan C; Schuster SJ
Blood; 2016 Feb; 127(8):1064-7. PubMed ID: 26702066
[No Abstract] [Full Text] [Related]
7. Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia.
Roeker LE; Sarraf Yazdy M; Rhodes J; Goodfriend J; Narkhede M; Carver J; Mato A
JAMA Netw Open; 2019 Dec; 2(12):e1916326. PubMed ID: 31790561
[TBL] [Abstract][Full Text] [Related]
8. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event.
Sollena P; Mannino M; Laurenti L; De Simone C; Peris K
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e342-e344. PubMed ID: 30989712
[No Abstract] [Full Text] [Related]
10. Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
Kolomeyer AM; Hwang CK; Kim BJ
J Med Case Rep; 2018 Nov; 12(1):349. PubMed ID: 30442199
[TBL] [Abstract][Full Text] [Related]
11. Resolution of eosinophilia and elevated immunoglobulin E with ibrutinib for chronic lymphocytic leukemia.
Harada K; Brooks JP; Lobo FM
Ann Allergy Asthma Immunol; 2018 Nov; 121(5):629-630.e1. PubMed ID: 30009879
[No Abstract] [Full Text] [Related]
12. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Mannis G; Wu D; Dea T; Mauro T; Hsu G
Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
[No Abstract] [Full Text] [Related]
13. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
[No Abstract] [Full Text] [Related]
14. Fludarabine causing tumour lysis syndrome in chronic lymphocytic leukaemia.
Mulligan SP; Dean MG
Aust N Z J Med; 1994 Aug; 24(4):406-7. PubMed ID: 7980241
[No Abstract] [Full Text] [Related]
15. Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Sun C; Gao J; Couzens L; Tian X; Farooqui MZ; Eichelberger MC; Wiestner A
JAMA Oncol; 2016 Dec; 2(12):1656-1657. PubMed ID: 27533065
[No Abstract] [Full Text] [Related]
16. Ventricular arrhythmias and sudden death in patients taking ibrutinib.
Lampson BL; Yu L; Glynn RJ; Barrientos JC; Jacobsen ED; Banerji V; Jones JA; Walewska R; Savage KJ; Michaud GF; Moslehi JJ; Brown JR
Blood; 2017 May; 129(18):2581-2584. PubMed ID: 28223277
[No Abstract] [Full Text] [Related]
17. Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
Gaye E; Le Bot A; Talarmin JP; Le Calloch R; Belaz S; Dupont M; Tattevin P
Med Mal Infect; 2018 Jun; 48(4):294-297. PubMed ID: 29402474
[No Abstract] [Full Text] [Related]
18. Ibrutinib induced acute tubular injury: A case series and review of the literature.
Manohar S; Bansal A; Wanchoo R; Sakhiya V; Lucia S; Jhaveri KD
Am J Hematol; 2019 Sep; 94(9):E223-E225. PubMed ID: 31148235
[No Abstract] [Full Text] [Related]
19. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
[No Abstract] [Full Text] [Related]
20. Ibrutinib-Induced Neutrophilic Dermatosis.
El Halabi L; Cherif-Rebai K; Michot JM; Ghez D
Am J Dermatopathol; 2018 Mar; 40(3):198-200. PubMed ID: 29473834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
